Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 4/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9341390 | 1.00 | SLC6A4 (0.61) | SLC6A4TAAR1SIGMAR1SLC18A2HPGD | |
| SCHEMBL12289294 | 1.00 | SLC6A4 (0.61) | SLC6A4TAAR1SIGMAR1SLC18A2HPGD | |
| SCHEMBL1697045 | 0.89 | SIGMAR1 (0.64) | SLC6A4TAAR1SIGMAR1SLC18A2EPHX1 | |
| SCHEMBL20393649 | 0.88 | SLC6A4 (0.59) | SLC6A4TAAR1SIGMAR1SLC18A2HTR1B | |
| SCHEMBL21243263 | 0.86 | SIGMAR1 (0.53) | SLC6A4TAAR1SIGMAR1SLC18A2HPGD | |
| SCHEMBL16174216 | 0.83 | BCHE (0.53) | SLC6A4SIGMAR1 | |
| SCHEMBL19043407 | 0.83 | BCHE (0.53) | SLC6A4SIGMAR1 | |
| SCHEMBL28207130 | 0.83 | SIGMAR1 (0.58) | SLC6A4TAAR1SIGMAR1SLC18A2EPHX1 | |
| SCHEMBL10287571 | 0.83 | SIGMAR1 (0.48) | SLC6A4TAAR1SIGMAR1SLC18A2HPGD | |
| SCHEMBL22783193 | 0.81 | SLC6A4 (0.65) | SLC6A4HTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION | 2015-01-01 | — | — | US | disclosed |
| US-20140309265-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | ENSEMBLE THERAPEUTICS (US) | 2014-10-16 | — | — | US | disclosed |
| EP-1255738-B1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20100076015-A1 | Aminopyridine Derivatives | VANTIA LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076015-A1 | Aminopyridine Derivatives | CHRM1, ARG1, ARG2 | SLC6A4 2762/4885TAAR1 661/4885SIGMAR1 1154/4885 |
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | IL17A, IL15, IL2 | SLC6A4 4879/4885TAAR1 4511/4885SIGMAR1 4471/4885 |
| US-20140309265-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | API5, BIRC5, BAD | SLC6A4 4739/4885TAAR1 4810/4885SIGMAR1 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.